542 related articles for article (PubMed ID: 26585576)
1. Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.
Huss M; Chen W; Ludolph AG
Clin Drug Investig; 2016 Jan; 36(1):1-25. PubMed ID: 26585576
[TBL] [Abstract][Full Text] [Related]
2. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
3. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Connor DF; Arnsten AF; Pearson GS; Greco GF
Expert Opin Pharmacother; 2014 Aug; 15(11):1601-10. PubMed ID: 24992513
[TBL] [Abstract][Full Text] [Related]
4. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
Childress A; Hoo-Cardiel A; Lang P
Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
[No Abstract] [Full Text] [Related]
6. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
8. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
9. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Erder MH; Xie J; Signorovitch JE; Chen KS; Hodgkins P; Lu M; Wu EQ; Sikirica V
Appl Health Econ Health Policy; 2012 Nov; 10(6):381-95. PubMed ID: 23113551
[TBL] [Abstract][Full Text] [Related]
11. Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy.
Schneider G; Banaschewski T; Feldman BL; Gustafsson PA; Murphy B; Reynolds M; Coghill DR; Spalding WM
J Child Adolesc Psychopharmacol; 2019 May; 29(4):285-304. PubMed ID: 30942617
[No Abstract] [Full Text] [Related]
12. Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).
Sallee FR; Eaton K
Expert Opin Pharmacother; 2010 Oct; 11(15):2549-56. PubMed ID: 20831361
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada.
Lachaine J; Ben Amor L; Pringsheim T; Burns J; van Stralen J
J Child Adolesc Psychopharmacol; 2019 Dec; 29(10):730-739. PubMed ID: 31433205
[No Abstract] [Full Text] [Related]
15. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy.
Ota T; Yamamuro K; Okazaki K; Kishimoto T
Drug Des Devel Ther; 2021; 15():1965-1969. PubMed ID: 34007156
[TBL] [Abstract][Full Text] [Related]
16. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
Findling RL; McBurnett K; White C; Youcha S
J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
[TBL] [Abstract][Full Text] [Related]
17. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
Wilens TE; McBurnett K; Turnbow J; Rugino T; White C; Youcha S
J Atten Disord; 2017 Jan; 21(2):110-119. PubMed ID: 24071772
[TBL] [Abstract][Full Text] [Related]
18. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
Connor DF; Rubin J
Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
[TBL] [Abstract][Full Text] [Related]
19. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
